BIOSTAR PHARMACEUTICALS INC

BIOSTAR PHARMACEUTICALS INC

OOTC:BSPM
0.00
USD
+0.00
(-99.00%)
0.35EPS
3.64P/E
3.40MMarket Cap

Total Valuation

USD

As of September 30, 2017, BIOSTAR PHARMACEUTICALS INC carries a market capitalization of 3.40M, placing it among publicly traded companies globally. Its enterprise value stands at 5.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.40M
Enterprise Value5.46M

Share Statistics

As of September 30, 2017, BIOSTAR PHARMACEUTICALS INC has 2.64M shares outstanding.

Shares Outstanding2.64M

Valuation Ratios

As of September 30, 2017, BIOSTAR PHARMACEUTICALS INC trades at a trailing price-to-earnings ratio of 3.64. The price-to-sales ratio is 10.70, and the price-to-book ratio stands at 0.09.

PE Ratio3.64
PS Ratio10.70
PB Ratio0.09
P/TBV Ratio0.11
P/FCF Ratio0.40
P/OCF Ratio0.40

Enterprise Valuation

As of September 30, 2017, BIOSTAR PHARMACEUTICALS INC trades at an EV/EBITDA multiple of 1.40 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 17.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BIOSTAR PHARMACEUTICALS INC trades at an EV/FCF ratio of 0.63, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 5.46M versus a market cap of 3.40M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales17.19
EV / EBITDA1.40
EV / EBIT1.96
EV / FCF0.63

Financial Position

As of September 30, 2017, BIOSTAR PHARMACEUTICALS INC maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.71, indicating elevated leverage, while an interest coverage ratio of 19.34 demonstrates strong ability to service its debt obligations.

Current Ratio0.19
Quick Ratio0.16
Debt / Equity6.71
Debt / EBITDA0.62
Interest Coverage19.34

Financial Efficiency

USD

Over the twelve months ended September 30, 2017, BIOSTAR PHARMACEUTICALS INC posted a return on equity (ROE) of 2.66, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.93 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.28, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.63, useful for judging operating efficiency across full business cycles. The company generates approximately 1,588.97 in revenue per employee across its workforce of 200.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.16 indicates how many times BIOSTAR PHARMACEUTICALS INC sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)2.66
Return on Assets (ROA)2.28
Return on Invested Capital (ROIC)1.93
Return on Capital Employed (ROCE)2.63
Revenue Per Employee1,588.97
Employee Count200.00
Inventory Turnover1.16

Taxes

USD

Over the twelve months ended September 30, 2017, BIOSTAR PHARMACEUTICALS INC recorded 2.65M in income tax expense. That works out to an effective tax rate of 73.95, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.59M, leaving 934,352.00 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax2.65M
Effective Tax Rate73.95

Stock Price Statistics

USD

As of the close on October 9, 2026, BIOSTAR PHARMACEUTICALS INC's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.08.

200-Day Moving Average0.08

Income Statement

USD

Over the twelve months ended September 30, 2017, BIOSTAR PHARMACEUTICALS INC generated 317,794.00 in revenue and converted that into 934,352.00 in net income, yielding earnings per share of 0.35. EBITDA reached 3.89M, while operating income came in at 2.84M.

Revenue317,794.00
Gross Profit-36,747.00
Operating Income2.84M
Pretax Income3.59M
Net Income934,352.00
EBITDA3.89M
EBIT2.79M
Earnings Per Share (EPS)0.35

Balance Sheet

USD

As of September 30, 2017, BIOSTAR PHARMACEUTICALS INC holds 364,973.00 in cash and equivalents against 2.43M in total debt, resulting in a net debt position of 2.06M. Total book value stands at 36.15M, with working capital of -4.28M providing operational flexibility.

Cash & Cash Equivalents364,973.00
Total Debt2.43M
Net Debt2.06M
Equity (Book Value)36.15M
Book Value Per Share13.71
Working Capital-4.28M

Cash Flow

USD

BIOSTAR PHARMACEUTICALS INC produced 8.59M in operating cash flow over the twelve months ended September 30, 2017.

Operating Cash Flow8.59M
Free Cash Flow8.59M
FCF Per Share3.26

Margins

Over the twelve months ended September 30, 2017, BIOSTAR PHARMACEUTICALS INC posted a gross margin of -11.56, reflecting its pricing power and cost economics. The operating margin of 893.30 and net profit margin of 294.01 provide insight into operational efficiency.

Gross Margin-11.56
Operating Margin893.30
Pretax Margin1,128.85
Profit Margin294.01
EBITDA Margin1,225.43

Dividends & Yields

These figures cover the twelve months ended September 30, 2017. Free cash flow yield stands at 252.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -49.74, meaning BIOSTAR PHARMACEUTICALS INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-49.74
FCF Yield252.42

Stock Splits

BIOSTAR PHARMACEUTICALS INC's most recent stock split took place on February 5, 2016 with a 7:1 split ratio.

Last Split Date2/5/2016
Split Ratio7:1

Scores

As of September 30, 2017, BIOSTAR PHARMACEUTICALS INC has an Altman Z-Score of 0.32, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score0.32